Oxytetracycline

Oxytetracycline

Basics

Oxytetracycline is a broad-spectrum antibiotic that is effective against a wide range of bacteria. However, some strains of bacteria have developed resistance to this antibiotic, which has reduced its effectiveness in treating some types of infections.
Oxytetracyclin wird zur Behandlung von Infektionen verwendet, die durch Chlamydien verursacht werden (z. B. Psittakose,Trachom und Urethritis) und Infektionen, die durch Mycoplasma-Organismen verursacht werden (z. B. Lungenentzündung).
Oxytetracyclin wird auch zur Behandlung von Akne eingesetzt und zur Behandlung von Schüben der chronischen Bronchitis eingesetzt. Außerdem kann es auch zur Behandlung von anderen, selteneren Infektionen eingesetzt werden, wie z. B. Rocky-Mountain-Fleckfieber.

Effect

Pharmacodynamics

Oxytetracycline inhibits cell growth by inhibiting protein translation. It binds to the 30S ribosomal subunit and prevents amino-acyl-tRNA binding to the A site of the ribosome. Oxytetracycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane. Binding to the bacterial ribosome prevents protein synthesis and thus pathogen replication.

Pharmacokinetics

Oxytetracycline is rapidly absorbed after oral administration.


Toxicity

Side effects

Side effects are mainly gastrointestinal and phototoxic reactions, which are typical for the group of tetracycline antibiotics. It can also damage calcium-rich organs, such as teeth and bones, but this is extremely rare. Candidiasis is also possible after treatment with broad-spectrum antibiotics.

Toxicological data

LD50 (rat, oral): 4800 mg-kg-1

Chemical & physical properties

ATC Code D06AA03, G01AA07, J01AA06, S01AA04
Formula C22H24N2O9
Molar Mass (g·mol−1) 460,44
Physical State solid
Melting Point (°C) 183
PKS Value 3.27
CAS Number 79-57-2
PUB Number 54675779
Drugbank ID DB00595

Editorial principles

All information used for the content comes from verified sources (recognised institutions, experts, studies by renowned universities). We attach great importance to the qualification of the authors and the scientific background of the information. Thus, we ensure that our research is based on scientific findings.
Markus Falkenstätter, BSc

Markus Falkenstätter, BSc
Author

Markus Falkenstätter is a writer on pharmaceutical topics in Medikamio's medical editorial team. He is in the last semester of his pharmacy studies at the University of Vienna and loves scientific work in the field of natural sciences.

Mag. pharm. Stefanie Lehenauer

Mag. pharm. Stefanie Lehenauer
Lector

Stefanie Lehenauer has been a freelance writer for Medikamio since 2020 and studied pharmacy at the University of Vienna. She works as a pharmacist in Vienna and her passion is herbal medicines and their effects.

The content of this page is an automated and high-quality translation from DeepL. You can find the original content in German here.

Ad

Your personal medicine assistent

afgis-Qualitätslogo mit Ablauf Jahr/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über medikamio GmbH & Co KG und sein/ihr Internet-Angebot: medikamio.com/ This website is certified by Health On the Net Foundation. Click to verify.
Drugs

Search our database for drugs, sorted from A-Z with their effects and ingredients.

Substances

All substances with their common uses, chemical components and medical products which contain them.

Diseases

Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.